Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | STS | P08842 | 3/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | VEGFA | P15692 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12492338 | 0.89 | MEN1 (0.43) | MEN1KMT2ADDB1CRBNCNR1 | |
| SCHEMBL8201517 | 0.88 | GPR119 (0.47) | KDM4E | |
| SCHEMBL14263456 | 0.81 | AGTR2 (0.39) | MEN1KMT2ACACNA1H | |
| SCHEMBL8204443 | 0.81 | GPR119 (0.50) | MEN1KMT2ADDB1CRBNKDM4E | |
| SCHEMBL8224867 | 0.81 | MEN1 (0.49) | MEN1KMT2ASTSNPSR1USP2 | |
| SCHEMBL8213940 | 0.81 | CACNA1H (0.59) | MEN1KMT2ASTSNPSR1VEGFA | |
| SCHEMBL3989232 | 0.78 | CACNA1H (0.46) | MEN1KMT2ASTSNPSR1HTT | |
| SCHEMBL4412451 | 0.78 | CACNA1H (0.59) | MEN1KMT2ASTSNPSR1USP2 | |
| SCHEMBL8207921 | 0.77 | GPR119 (0.49) | DDB1CRBNHSD17B10 | |
| SCHEMBL3613790 | 0.76 | MEN1 (0.47) | MEN1KMT2ASTSDDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884080-B2 | Administering an azetidinone compound for treating a disorder of lipid metabolism, pain, diabetes, a vascular condition, demyelination or nonalcoholic fatty liver disease; T-type calcium channel blocking agent, an antagonist of TRPV1, an agonist of TRPV1, of GPR119, antagonist of NPCL1 | SCHERING PLOUGH CORPORATION (US) | 2011-02-08 | — | — | US | disclosed |
| US-7884080-B2 | Administering an azetidinone compound for treating a disorder of lipid metabolism, pain, diabetes, a vascular condition, demyelination or nonalcoholic fatty liver disease; T-type calcium channel blocking agent, an antagonist of TRPV1, an agonist of TRPV1, of GPR119, antagonist of NPCL1 | SCHERING PLOUGH CORPORATION (US) | 2011-02-08 | — | — | US | disclosed |
| US-7638526-B2 | Azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabolism | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-7638526-B2 | Azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabolism | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-7638526-B2 | Azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabolism | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| EP-2066316-A1 | AZETIDINE AND AZETIDONE DERIVATIVES USEFUL IN TREATING PAIN AND DISORDERS OF LIPID METABOLISM | SCHERING CORPORATION (US) | 2009-06-10 | — | — | EP | disclosed |
| EP-2061791-A1 | SPIRO-CONDENSED AZETIDINE DERIVATIVES USEFUL IN TREATING PAIN, DIABETES AND DISORDERS OF LIPID METABILISM | SCHERING CORPORATION (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080089858-A1 | AZETIDINE DERIVATIVES USEFUL IN TREATING PAIN, DIABETES AND DISORDERS OF LIPID METABOLISM | SCHERING CORPORATION | 2008-04-17 | — | — | US | disclosed |
| US-20080089858-A1 | AZETIDINE DERIVATIVES USEFUL IN TREATING PAIN, DIABETES AND DISORDERS OF LIPID METABOLISM | SCHERING CORPORATION | 2008-04-17 | — | — | US | disclosed |
| US-20080089858-A1 | AZETIDINE DERIVATIVES USEFUL IN TREATING PAIN, DIABETES AND DISORDERS OF LIPID METABOLISM | SCHERING CORPORATION | 2008-04-17 | — | — | US | disclosed |
| US-20080076751-A1 | Azetidinone Derivatives and Methods of Use Thereof | MERCK SHARP & DOHME CORP. | 2008-03-27 | — | — | US | disclosed |
| US-20080076751-A1 | Azetidinone Derivatives and Methods of Use Thereof | MERCK SHARP & DOHME CORP. | 2008-03-27 | — | — | US | disclosed |
| US-20080076750-A1 | Azetidinone Derivatives and Methods of Use Thereof | SCHERING CORPORATION | 2008-03-27 | — | — | US | disclosed |
| US-20080070892-A1 | TREATING PAIN, DIABETES, AND DISORDERS OF LIPID METABOLISM | SCHERING CORPORATION | 2008-03-20 | — | — | US | disclosed |
| WO-2008033447-A1 | AZETIDINE AND AZETIDONE DERIVATIVES USEFUL IN TREATING PAIN AND DISORDERS OF LIPID METABOLISM | SCHERING CORPORATION (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008033460-A2 | TREATING PAIN, DIABETES, AND LIPID METABOLISM DISORDERS | SCHERING CORPORATION (US) | 2008-03-20 | — | — | WO | disclosed |
| US-20080070888-A1 | AZETIDINE AND AZETIDONE DERIVATIVES USEFUL IN TREATING PAIN AND DISORDERS OF LIPID METABOLISM | SCHERING CORPORATION | 2008-03-20 | — | — | US | disclosed |
| WO-2008033456-A1 | SPIRO-CONDENSED AZETIDINE DERIVATIVES USEFUL IN TREATING PAIN, DIABETES AND DISORDERS OF LIPID METABILISM | SCHERING CORPORATION (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008033456-A1 | SPIRO-CONDENSED AZETIDINE DERIVATIVES USEFUL IN TREATING PAIN, DIABETES AND DISORDERS OF LIPID METABILISM | SCHERING CORPORATION (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008033464-A2 | AZETIDINONE DERIVATIVES FOR THE TREATMENT OF DISORDERS OF THE LIPID METABOLISM | SCHERING CORPORATION (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080089858-A1 | AZETIDINE DERIVATIVES USEFUL IN TREATING PAIN, DIABETES AND DISORDERS OF LIPID METABOLISM | GPR119, PNLIP, CYP46A1 | MEN1 3422/4885KMT2A 3822/4885STS 2282/4885 |
| US-20080076750-A1 | Azetidinone Derivatives and Methods of Use Thereof | LIPC, CES1, ZDHHC20 | MEN1 1687/4885KMT2A 3236/4885STS 393/4885 |
| US-20080070892-A1 | TREATING PAIN, DIABETES, AND DISORDERS OF LIPID METABOLISM | PNLIP, LIPC, LIPE | MEN1 3144/4885KMT2A 3229/4885STS 1413/4885 |
| US-20080070888-A1 | AZETIDINE AND AZETIDONE DERIVATIVES USEFUL IN TREATING PAIN AND DISORDERS OF LIPID METABOLISM | OPRD1, OPRK1, OPRL1 | MEN1 3532/4885KMT2A 2918/4885STS 2304/4885 |
| US-20080076751-A1 | Azetidinone Derivatives and Methods of Use Thereof | LIPC, ZDHHC20, FABP1 | MEN1 1858/4885KMT2A 3586/4885STS 1634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.